ReviewDrugs2018
Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.
Review in Drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Chronic Obstructive Pulmonary Disease and Lung Cancer: A Meta-Analysis of Risk Association.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- Peripheral Blood Inflammatory Markers and Immune Cell Profiles in Smokers With and Without COPD.Pulmonary therapy · 2026Article
- Integrating Machine Learning for Early COPD Prediction in Lung Cancer Patients: A Focus on Systemic Coagulation-Inflammation Index.International journal of chronic obstructive pulmonary disease · 2026Article
- Redefining the Diagnostic and Therapeutic Landscape of Non-Small Cell Lung Cancer in the Era of Precision Medicine.Journal of clinical medicine · 2025Review
- Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Inflammation, tertiary lymphoid structures, and lung cancer: a bibliometric analysis.Translational lung cancer research · 2024Article
- Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary.Respiratory research · 2024Review
- Review
- Role of ATG4 Autophagy-Related Protein Family in the Lower Airways of Patients with Stable COPD.International journal of molecular sciences · 2024Article
- Altered hypoxia-induced cellular responses and inflammatory profile in lung fibroblasts from COPD patients compared to control subjects.Respiratory research · 2024Article
- Review
- Differential expression of mast cells in the small airways and alveolar septa of current smokers and patients with small airway disease and COPD.ERJ open research · 2024Article
- Efficacy and safety of pembrolizumab as first-line treatment for advanced non-small cell lung cancer complicated with chronic obstructive pulmonary disease: protocol for a prospective, single-arm, single-center, phase II clinical trial.Frontiers in oncology · 2024Article
- Endothelial to mesenchymal transition is an active process in smokers and patients with early COPD contributing to pulmonary arterial pathology.ERJ open research · 2024Article
- Inflammatory factors and risk of lung adenocarcinoma: a Mendelian randomization study mediated by blood metabolites.Frontiers in endocrinology · 2024Article
- Epithelial-mesenchymal transition changes in nonsmall cell lung cancer patients with early COPD.ERJ open research · 2023Article
- Clinical evaluation of ventilation mode on acute exacerbation of chronic obstructive pulmonary disease with respiratory failure.World journal of clinical cases · 2023Article
- The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs.International journal of molecular sciences · 2023Review
- Study on the mechanism of oral administration of tetrandrine during neoadjuvant chemotherapy for colon cancer.Oncology letters · 2023Article
- Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 11 institutions in 4 countries.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) and lung cancer are major lung diseases affecting millions worldwide. Both diseases have links to cigarette smoking and exert a considerable societal burden. People suffering from COPD are at higher risk of developing lung cancer than those without, and are more susceptible to poor outcomes after diagnosis and treatment. Lung cancer and COPD are closely associated, possibly sharing common traits such as an underlying genetic predisposition, epithelial and endothelial cell plasticity, dysfunctional inflammatory mechanisms including the deposition of excessive extracellular matrix, angiogenesis, susceptibility to DNA damage and cellular mutagenesis. In fact, COPD could be the driving factor for lung cancer, providing a conducive environment that propagates its evolution. In the early stages of smoking, body defences provide a combative immune/oxidative response and DNA repair mechanisms are likely to subdue these changes to a certain extent; however, in patients with COPD with lung cancer the consequences could be devastating, potentially contributing to slower postoperative recovery after lung resection and increased resistance to radiotherapy and chemotherapy. Vital to the development of new-targeted therapies is an in-depth understanding of various molecular mechanisms that are associated with both pathologies. In this comprehensive review, we provide a detailed overview of possible underlying factors that link COPD and lung cancer, and current therapeutic advances from both human and preclinical animal models that can effectively mitigate this unholy relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.